Hannah focuses her practice on securities and capital markets transactions, public offerings, and general corporate matters. Hannah represents clients in a variety of industries, including life sciences, technology, investment banks and other financial services firms. Hannah has experience with representing both issuers and underwriters in a variety of capital markets transactions, including reverse mergers, follow-on offerings, and at-the-market offerings.
While attending law school, Hannah worked as law clerk at an estate planning law firm, a tax law firm, and a consulting company specializing in advising entrepreneurs, all of which are based in San Diego. In those roles, she gained experience in estate planning, trust administration, probate matters, criminal and civil tax audits, and general corporate work. She also served as a corporate counsel extern to a San Diego–based company that provides consumer financing for renewable energy and energy-efficiency projects.
In law school, she received numerous scholarships and worked for two professors, as a tax & estate legal research assistant and an IP/contract law research assistant.
viewpoints
Court Vacates SEC’s New Share Repurchase Disclosure Rules
December 21, 2023 | Advisory | By Daniel T. Kajunski, Hannah L. Karraker
Read about the Fifth Circuit’s December 19 opinion vacating the Securities and Exchange Commission’s share repurchase disclosure rules, which were adopted in May 2023 and became effective on July 31, 2023.
SEC Adopts New Share Repurchase Disclosure Rules
May 18, 2023 | Alert | By Daniel T. Kajunski, Hannah L. Karraker
Read about the SEC’s final rules requiring increased quantitative data and expanded narrative disclosure regarding share repurchases by an issuer.
SEC Adopts Amendments Requiring Electronic Filing of Forms 144
November 2, 2022 | Alert | By Hannah L. Karraker
Read about how the SEC’s adoption of an electronic filing mandate for certain documents, including all Forms 144 for the sale of securities by US public company issuers, could impact public companies.
News & Press
Mintz Advises the Placement Agents in CAMP4’s up to $100 Million Private Placement
September 12, 2025
Mintz advised the placement agents in connection with CAMP4's up to $100 million private placement. The private placement included upfront gross proceeds of $50 million in exchange for common stock (and pre-funded warrants in lieu of common stock for certain investors). In addition, CAMP4 will be eligible to receive up to an additional $50 million in gross proceeds in exchange for common stock (and pre-funded warrants for certain investors), subject to achieving pre-specified milestones, including receipt of regulatory clearance to initiate a Phase 1/2 clinical trial in SYNGAP patients with its development candidate, CMP-SYNGAP-01.
Mintz Advises the Underwriters in Ondas Holdings’ $230 Million Underwritten Offering
September 11, 2025
Mintz advised the underwriters in connection with the $230 million underwritten offering by Ondas Holdings Inc. of 46,000,000 shares of its common stock, which includes 6,000,000 shares of common stock sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock.
Mintz Advises Underwriters in Assembly Biosciences' $175 Million Underwritten Offering and Concurrent Private Placement
August 18, 2025
Mintz advised the underwriters in connection with Assembly Biosciences, Inc.’s underwritten offering of an aggregate of 5,591,840 shares of common stock and pre-funded warrants to purchase up to 1,040,820 shares of common stock, together with accompanying Class A and Class B warrants to purchase up to an aggregate of 6,632,660 shares of common stock at a combined price per share of common stock and accompanying Class A warrant and Class B warrant of $19.60 and a combined price per pre-funded warrant and accompanying Class A warrant and Class B warrant of $19.599.
Mintz advised the underwriters in connection with the $173 million public offering by Ondas Holdings Inc. of 53,084,000 shares of its common stock, which includes 6,924,000 shares of common stock sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock.
Mintz Advises Aspen Aerogels on $98M Follow-on Offering
November 19, 2024
Mintz advised Aspen Aerogels, Inc. (NYSE: ASPN), a technology leader in sustainability and electrification solutions, on a registered follow-on offering of 4,887,500 shares of its common stock, which included 637,500 shares pursuant to the underwriters’ option to purchase additional shares of its common stock. The price to the public in the offering was $20.00 per share and the gross proceeds to Aspen from the offering were approximately $98 million, before deducting underwriting discounts and commissions and estimated offering expenses.
Recognition & Awards
USD Alumni Torts Tournament First Place Brief (2020)
Saul Lefkowitz Moot Court Tournament, Third Place (2019)
Order of Barristers (2021)
Recent Insights
Mintz advised the placement agents in connection with CAMP4's up to $100 million private placement. The private placement included upfront gross proceeds of $50 million in exchange for common stock (and pre-funded warrants in lieu of common stock for certain investors). In addition, CAMP4 will be eligible to receive up to an additional $50 million in gross proceeds in exchange for common stock (and pre-funded warrants for certain investors), subject to achieving pre-specified milestones, including receipt of regulatory clearance to initiate a Phase 1/2 clinical trial in SYNGAP patients with its development candidate, CMP-SYNGAP-01.
Mintz advised the underwriters in connection with the $230 million underwritten offering by Ondas Holdings Inc. of 46,000,000 shares of its common stock, which includes 6,000,000 shares of common stock sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock.
Mintz advised the underwriters in connection with Assembly Biosciences, Inc.’s underwritten offering of an aggregate of 5,591,840 shares of common stock and pre-funded warrants to purchase up to 1,040,820 shares of common stock, together with accompanying Class A and Class B warrants to purchase up to an aggregate of 6,632,660 shares of common stock at a combined price per share of common stock and accompanying Class A warrant and Class B warrant of $19.60 and a combined price per pre-funded warrant and accompanying Class A warrant and Class B warrant of $19.599.
